Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/effect-of-a-single-daily-dose-treatment-of-fenofibrate-on-plasma-wzOqkZpcmB
References (31)
-
Claude Malmendier, C. Delcroix (1985)
Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.Atherosclerosis, 55 2
-
C. Harvengt, F. Heller, J. Desager (1980)
Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.Artery, 7 1
-
P. Wilson, L. Zech, R. Gregg, E. Schaefer, J. Hoeg, D. Sprecher, H. Brewer (1985)
Estimation of VLDL cholesterol in hyperlipidemia.Clinica chimica acta; international journal of clinical chemistry, 151 3
-
F. Heller, C. Harvengt (2004)
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjectsEuropean Journal of Clinical Pharmacology, 25
-
D. Kritchevsky (1980)
Pharmacologie du fénofibrate.La Nouvelle presse médicale, 9
-
(1986)
Cholesterol lowering and the re -
(1982)
Increase of lipoproteinlipase activity after procetophen ( Feno - fibrate ) treatment in primary hyperlipoproteinemia -
J. Shepherd, M. Caslake, A. Lorimer, B. Vallance, C. Packard (1985)
Fenofibrate Reduces Low Density Lipoprotein Catabolism in Hypertriglyceridemic SubjectsArteriosclerosis, Thrombosis, and Vascular Biology, 5
-
J. Desager, C. Harvengt (1978)
Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers.International journal of clinical pharmacology and biopharmacy, 16 12
-
(1987)
The Hyperlipoproteinemias and other disorders of the lipid metabolism -
(1980)
Activite du feno - fibrate dans quatre types d ' hyperlipoproteinemie et sur les apoproteines A et B dans le type IIA -
R. Brodie, L. Chasseaud, F. Elson, E. Franklin, T. Taylor (1976)
Antilipidemic drugs. Part 4: The metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man.Arzneimittel-Forschung, 26 5
-
(1976)
Antilipidemic drugs -
(1979)
Drug plasma levels and hypocholesterotemic effect of fenofibrate in patients with type IIA hyperlipoproteinemia -
(1985)
Estimation of VLDL -
A. Ramusino, A. Carozzi (1986)
Simple and rapid method for determining procetofenic acid, an active metabolite of procetofen, in biological fluids by solid-phase extraction and high-performance liquid chromatography.Journal of chromatography, 383 2
-
(1981)
Fenofibrate therapy of Hyperlipopro -
S. Grundy (1990)
Cholesterol and coronary heart disease.Scandinavian journal of clinical and laboratory investigation. Supplementum, 199
-
(1980)
Hypolipemic and hy - pouricemic action of fenofibrate in various types of hyper - lipoproteinemia -
(1980)
Pharmacologic du fenofibrate -
D. Sommariva, D. Bonfiglioli, I. Pogliaghi, C. Ottomano, A. Fasoli (2004)
Fenofibrate therapy of hypertriglyceridaemias. Differential effects on LDL cholesterol level in Type IV and in Type IIb primary hyperlipoproteinaemiaEuropean Journal of Clinical Pharmacology, 26
-
(1983)
Influence of bezafi - brate , fenofibrate , nicotinic acid and etofibrate on plasma high density lipoproteins levels -
A. Schneider, E. Stange, H. Ditschuneit, H. Ditschuneit (1985)
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.Atherosclerosis, 56 3
-
(1985)
Effects of fenofibrate -
L. Gidez, G. Miller, M. Burstein, S. Slagle, H. Eder (1982)
Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure.Journal of lipid research, 23 8
-
B. Rifkind, C. Lenfant (1986)
Cholesterol lowering and the reduction of coronary heart disease risk.JAMA, 256 20
-
E. Wulfert, G. Boissard, C. Legendre, C. Baron (1981)
Inhibition of membrane-bound hepatic 3 hydroxy-3 methyl glutaryl CoA reductase as the consequence of altered membrane fluidity.Artery, 9 2
-
R. Paoletti, G. Franceschini, C. Sirtori (1983)
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.The American journal of cardiology, 52 4
-
S. Grundy (1986)
Cholesterol and coronary heart disease. A new era.JAMA, 256 20
-
S. Rössner, L. Orö (1981)
Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.Atherosclerosis, 38 3-4
-
(1985)
Fenofibrate reduces low density lipoprotein
- Publisher
- Springer Journals
- Copyright
- Copyright © 1988 by Springer-Verlag
- Subject
- Biomedicine; Pharmacology/Toxicology
- ISSN
- 0031-6970
- eISSN
- 1432-1041
- DOI
- 10.1007/BF01061412
- Publisher site
- See Article on Publisher Site
Abstract
228 34 34 1 1 S. Bertolini N. Elicio A. Daga M. L. Degl'Innocenti R. Balestreri M. G. Fusi A. M. Cotta Ramusino A. Carozzi Atherosclerosis Prevention Center, Department of Internal Medicine University of Genoa Genoa Italy Clinical Research Department SELVI 3M Milan Italy Summary The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.
Journal
European Journal of Clinical Pharmacology – Springer Journals
Published: Jan 1, 1988